TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31820598

Group type: EXPERIMENTAL
Intervention: NRT group
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Acupuncture plus auricular therapy group
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Auricular therapy group
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Acupuncture group
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: TENS group
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: FTND score and HSI score
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Regression analysis
Number of subjects: 500
Study: 28122157

Group type: EXPERIMENTAL
Intervention: Caregiver-delivered reflexology intervention
Number of subjects: 0
Study: 25774586

Group type: EXPERIMENTAL
Intervention: Ramipril 2.5 mg/day
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ramipril 10 mg/day
Number of subjects: 20
Study: 23532746

Group type: EXPERIMENTAL
Intervention: MK-8998 12/16 mg daily
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Olanzapine 10/15 mg daily
Number of subjects: 216

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: MK-8998
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: MK-8998 and Olanzapine
Number of subjects: 216
Study: 21395892

Group type: EXPERIMENTAL
Intervention: Crushed buprenorphine (2 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Crushed buprenorphine (8 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Crushed buprenorphine/naloxone (2/0.5 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Crushed buprenorphine/naloxone (8/2 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Intravenous buprenorphine/naloxone (0.8 mg buprenorphine/0.2 mg naloxone)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: All intranasal doses
Number of subjects: 10
Study: 18492551

Group type: EXPERIMENTAL
Intervention: Imagery trip CD (experimental group)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 60
Study: 16581623

Group type: EXPERIMENTAL
Intervention: Attachment-focused (AF) group intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Relationship skills-focused (RS) group intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: No-intervention control (NC)
Number of subjects: 0
Study: 12585984

Group type: EXPERIMENTAL
Intervention: Breast self-examination
Number of subjects: 266000
Study: 10919340

Group type: EXPERIMENTAL
Intervention: 20 mg enalapril wafer
Number of subjects: 16

Group type: COMPARATOR
Intervention: 20 mg enalapril tablet
Number of subjects: 16
Study: 8986932

Group type: EXPERIMENTAL
Intervention: Bunazosin retard
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 95

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study: 1731452

Group type: EXPERIMENTAL
Intervention: Timolol (10 mg twice daily)
Number of subjects: 28
Study: 6212035

Group type: EXPERIMENTAL
Intervention: Piperacillin and gentamicin
Number of subjects: 32

Group type: COMPARATOR
Intervention: Carbenicillin and gentamicin
Number of subjects: 32
Study: 31113310

Group type: EXPERIMENTAL
Intervention: Tailored feedback
Number of subjects: 48

Group type: COMPARATOR
Intervention: Self-feedback
Number of subjects: 48

Group type: COMPARATOR
Intervention: Pamphlet
Number of subjects: 48
Study: 29862877

Group type: EXPERIMENTAL
Intervention: Illumination at 3 and 4 hours after MAL-application (3/4 group)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Illumination at 3 and 5 hours after MAL-application (3/5 group)
Number of subjects: 30
Study: 28457847

Group type: EXPERIMENTAL
Intervention: Mechanical curettage + adjunct antimicrobial photodynamic therapy (MC + aPDT)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Mechanical curettage alone (MC)
Number of subjects: 54
Study: 26054138

Group type: EXPERIMENTAL
Intervention: Transcutaneous acupoint electrical stimulation applied to Ciliao (BL 32), Shenshu (BL 23), Zigong (EX‐CA 1), Guanyuan (CV 4) and Qihai (CV 6), once a day for 4 weeks.
Number of subjects: 90

Group type: COMPARATOR
Intervention: Oral administration of midodrine hydrochloride tablets, 2.5 mg per treatment, three times each day for 4 weeks.
Number of subjects: 90
Study: 23317780

Group type: EXPERIMENTAL
Intervention: 1-piece Tecnis 1 ZCB00 IOL
Number of subjects: 62

Group type: COMPARATOR
Intervention: 3-piece Sensar AR40e IOL
Number of subjects: 62
Study: 22085421

Group type: EXPERIMENTAL
Intervention: In-home intervention with trained paraprofessional instructor and reinforcement telephone contacts
Number of subjects: 372

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 372

Group type: EXPERIMENTAL
Intervention: In-home intervention
Number of subjects: 372
Study: 19506195

Group type: EXPERIMENTAL
Intervention: Age-standardized prevalence of dry eye disease (DED) among men 50 years and older
Number of subjects: 25644

Group type: EXPERIMENTAL
Intervention: Age-related prevalence of DED
Number of subjects: 25644

Group type: EXPERIMENTAL
Intervention: Risk factors associated with DED
Number of subjects: 25644

Group type: EXPERIMENTAL
Intervention: Medication use associated with DED
Number of subjects: 25644
Study: 19839175

Group type: EXPERIMENTAL
Intervention: Unipedal stance test (UPST) with eyes open
Number of subjects: 549

Group type: EXPERIMENTAL
Intervention: Unipedal stance test (UPST) with eyes closed
Number of subjects: 549
Study: 15671911

Group type: EXPERIMENTAL
Intervention: High doses of vitamin C
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 12069109

Group type: EXPERIMENTAL
Intervention: CoQ10 supplementation (300mg per day for four weeks)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 9793662

Group type: EXPERIMENTAL
Intervention: Clonidine-bupivacaine
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Morphine-bupivacaine
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo-bupivacaine
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 36
Study: 7699443

Group type: EXPERIMENTAL
Intervention: Fast SPECT technique for stress imaging
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Fast SPECT technique for rest imaging
Number of subjects: 44

Group type: COMPARATOR
Intervention: Standard SPECT technique for stress imaging
Number of subjects: 44

Group type: COMPARATOR
Intervention: Standard SPECT technique for rest imaging
Number of subjects: 44
Study: 2692982

Group type: EXPERIMENTAL
Intervention: Ceftriaxone plus amikacin
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Ceftazidime plus amikacin
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Imipenem/cilastatin
Number of subjects: 27
Study: 368852

Group type: EXPERIMENTAL
Intervention: Self-hypnosis technique (HT)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Meditational relaxation technique (MT)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Moderate-high responsivity (HT or MT)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Low responsivity HT (Control)
Number of subjects: 32
Study: 31026557

Group type: EXPERIMENTAL
Intervention: TTFields with average LMiDD ≥0.77 mW/cm3
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: TTFields with average intensity >1.06 V/cm
Number of subjects: 340
Study: 27773846

Group type: EXPERIMENTAL
Intervention: Abdominal ultrasonography by an emergency department physician
Number of subjects: 1666

Group type: EXPERIMENTAL
Intervention: Abdominal ultrasonography by a radiologist
Number of subjects: 1666

Group type: COMPARATOR
Intervention: Abdominal computerized tomography
Number of subjects: 1666
Study: 25813765

Group type: EXPERIMENTAL
Intervention: Riociguat (up to 2.5 mg 3 times a day for 16 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 23590451

Group type: EXPERIMENTAL
Intervention: Intensive management (ultrasound scan, maternal serum hPL, induction of labour if either result was abnormal)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard management (ultrasound scan if indicated, induction of labour based on consultant decision)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Both groups (standard and intensive management)
Number of subjects: 120
Study: 21757677

Group type: EXPERIMENTAL
Intervention: Robot-assisted therapy
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Intensive comparison therapy
Number of subjects: 127

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 127
Study: 19209016

Group type: EXPERIMENTAL
Intervention: Aprepitant (secondary prophylaxis)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Standard antiemetic prophylaxis (5-HT3 receptor antagonist and dexamethasone)
Number of subjects: 109
Study: 17986903

Group type: EXPERIMENTAL
Intervention: Cr-Protein-Carbohydrate (Cr-PRO-CHO) supplement (1.5 g x kg(‐1) body weight x d(‐1) and 0.1 g x kg(‐1) body weight x d(‐1) of creatine)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Protein-Carbohydrate (PRO-CHO) supplement
Number of subjects: 3

Group type: COMPARATOR
Intervention: Protein (PRO) supplement
Number of subjects: 3
Study: 15249409

Group type: EXPERIMENTAL
Intervention: Ilioinguinal nerve preservation (group A)
Number of subjects: 813

Group type: COMPARATOR
Intervention: Elective transection (group B)
Number of subjects: 813

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 813
Study: 12040275

Group type: EXPERIMENTAL
Intervention: Chemoradiation (radiation plus chemotherapy)
Number of subjects: 1528

Group type: COMPARATOR
Intervention: Radiation therapy alone (control arm)
Number of subjects: 1528
Study: 9660430

Group type: EXPERIMENTAL
Intervention: Oral micronized DHEA (25 mg/d)
Number of subjects: 13
Study: 7664230

Group type: EXPERIMENTAL
Intervention: Physicians who viewed episiotomy very unfavorably
Number of subjects: 447

Group type: EXPERIMENTAL
Intervention: Physicians who viewed episiotomy favorably
Number of subjects: 447

Group type: EXPERIMENTAL
Intervention: Physicians who viewed episiotomy very favorably
Number of subjects: 447
Study: 2654790

Group type: EXPERIMENTAL
Intervention: Cytosine arabinoside (Ara‐C) at high dose (3.0 g/m2)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Cytosine arabinoside (Ara‐C) at intermediate dose (1.0 g/m2)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Cytosine arabinoside (Ara‐C) at low dose (0.5 g/m2)
Number of subjects: 51
Study: 319122

Group type: EXPERIMENTAL
Intervention: Meptazinol (400-mg capsules)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30369370

Group type: EXPERIMENTAL
Intervention: Combined 2Hz acupuncture anesthesia (Group A)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Combined 2Hz/100Hz acupuncture anesthesia (Group B)
Number of subjects: 110
Study: 26645242

Group type: EXPERIMENTAL
Intervention: Voice therapy
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: Phonosurgery
Number of subjects: 276

Group type: COMPARATOR
Intervention: Control group (no voice impairment)
Number of subjects: 276
Study: 24532471

Group type: EXPERIMENTAL
Intervention: Speed-feedback therapy with a bicycle ergometer (once a week for four weeks)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Routine activities (control group)
Number of subjects: 78
Study: 22617224

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 528

Group type: COMPARATOR
Intervention: Bisoprolol
Number of subjects: 528
Study: 19539385

Group type: EXPERIMENTAL
Intervention: External counterpulsation (ECP) over 7 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: External counterpulsation (ECP)
Number of subjects: 0
Study: 17611739

Group type: EXPERIMENTAL
Intervention: bromocriptine (2.5 mg)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: pergolide (0.1 mg)
Number of subjects: 15

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 15
Study: 16518971

Group type: EXPERIMENTAL
Intervention: Enema
Number of subjects: 1001

Group type: COMPARATOR
Intervention: No-enema
Number of subjects: 1001
Study: 11834878

Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 10428996

Group type: EXPERIMENTAL
Intervention: r‐EPO five times a week (500 U/kg)
Number of subjects: 80

Group type: COMPARATOR
Intervention: r‐EPO two times a week (500 U/kg)
Number of subjects: 80
Study: 8801107

Group type: EXPERIMENTAL
Intervention: Salmeterol 50 micrograms bd
Number of subjects: 847

Group type: COMPARATOR
Intervention: Salmeterol 25 micrograms bd
Number of subjects: 847

Group type: COMPARATOR
Intervention: Salbutamol 200 micrograms bd
Number of subjects: 847
Study: 2086265

Group type: EXPERIMENTAL
Intervention: Posterior repelling magnet splints
Number of subjects: 20

Group type: COMPARATOR
Intervention: Acrylic posterior bite‐blocks
Number of subjects: 20
Study: 146916

Group type: EXPERIMENTAL
Intervention: Aromatic ethylamide derivative of retinoic acid (Ro. 11‐1430) applied topically for 10 weeks
Number of subjects: 50

Group type: COMPARATOR
Intervention: Topical retinoic acid
Number of subjects: 50
Study: 30948567

Group type: EXPERIMENTAL
Intervention: APAP
Number of subjects: 0

Group type: COMPARATOR
Intervention: fixed CPAP
Number of subjects: 0
Study: 28554486

Group type: EXPERIMENTAL
Intervention: Aspirin plus ticagrelor 90 mg once daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aspirin plus ticagrelor 45 mg twice daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aspirin plus clopidogrel 75 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Comparison between low-dose ticagrelor groups (90 mg QD and 45 mg BID)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ticagrelor 90 mg QD
Number of subjects: 0
Study: 25650503

Group type: EXPERIMENTAL
Intervention: Vortioxetine (10 mg/day)
Number of subjects: 424

Group type: COMPARATOR
Intervention: Venlafaxine XR (150 mg/day)
Number of subjects: 424

Group type: EXPERIMENTAL
Intervention: Vortioxetine
Number of subjects: 424

Group type: COMPARATOR
Intervention: Venlafaxine XR
Number of subjects: 424

Group type: EXPERIMENTAL
Intervention: Vortioxetine and Venlafaxine XR
Number of subjects: 424
Study: 23199818

Group type: EXPERIMENTAL
Intervention: Classic padded bandage
Number of subjects: 409

Group type: COMPARATOR
Intervention: Polyurethane heel
Number of subjects: 409
Study: 21784096

Group type: EXPERIMENTAL
Intervention: exercise self-regulation intervention
Number of subjects: 725

Group type: COMPARATOR
Intervention: online questionnaire (control)
Number of subjects: 725
Study: 19345831

Group type: EXPERIMENTAL
Intervention: Moxifloxacin (400 mg) with ethambutol placebo
Number of subjects: 170

Group type: COMPARATOR
Intervention: Ethambutol (15-20 mg/kg) plus moxifloxacin placebo
Number of subjects: 170
Study: 16938698

Group type: EXPERIMENTAL
Intervention: Prospective memory targets preceded by associated primes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Specific context instructions provided to participants
Number of subjects: 0

Group type: COMPARATOR
Intervention: No specific context instructions provided to participants
Number of subjects: 0
Study: 15259323

Group type: EXPERIMENTAL
Intervention: Revised landmark task
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 0
Study: 11296057

Group type: EXPERIMENTAL
Intervention: Budesonide aqueous nasal spray, 128 microg once daily in the morning and placebo in the evening
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Budesonide aqueous nasal spray, 128 microg twice daily
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Budesonide aqueous nasal spray, 256 microg once daily in the morning and placebo in the evening
Number of subjects: 183

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 183
Study: 9245962

Group type: EXPERIMENTAL
Intervention: 10 mM mangafodipir trisodium infusion (MnDPDP) administered at doses of 5 and 10 mumol/kg b.w. by bolus injection (< 1 min) to 5 subjects and by infusion (20 min) to 8 subjects.
Number of subjects: 13
Study: 8320931

Group type: EXPERIMENTAL
Intervention: Intermittent machine haemofiltration
Number of subjects: 30

Group type: COMPARATOR
Intervention: Continuous hemofiltration and/or dialysis
Number of subjects: 30
Study: 3788228

Group type: EXPERIMENTAL
Intervention: Cimetidine (3 X 200 mg plus 1 X 400 mg daily for one week)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Ranitidine (2 X 150 mg daily for one week)
Number of subjects: 12
Study: 31473291

Group type: EXPERIMENTAL
Intervention: Caloric Supplementation (CS)
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Drug Holidays (DH)
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Weight Recovery Treatments (WRT) overall
Number of subjects: 230

Group type: COMPARATOR
Intervention: CNS Stimulants
Number of subjects: 230
Study: 30239134

Group type: EXPERIMENTAL
Intervention: Multidisciplinary Cardiac Rehabilitation (CR) program
Number of subjects: 655

Group type: COMPARATOR
Intervention: No participation in the CR program (Control)
Number of subjects: 655
Study: 28657378

Group type: EXPERIMENTAL
Intervention: QS‐Nd:YAG laser plus microneedling with vitamin C (Group A)
Number of subjects: 16

Group type: COMPARATOR
Intervention: QS‐Nd:YAG laser alone (Group B)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Adverse effects and recurrence rates
Number of subjects: 16
Study: 26614519

Group type: EXPERIMENTAL
Intervention: PBL approach with two case scenarios for small group discussion
Number of subjects: 52

Group type: COMPARATOR
Intervention: Ordinary teaching and learning (Control)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: PBL approach
Number of subjects: 52
Study: 23124915

Group type: EXPERIMENTAL
Intervention: Dairy-based foods
Number of subjects: 20

Group type: COMPARATOR
Intervention: Vegetable oil-based foods
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Dairy-based foods and Vegetable oil-based foods
Number of subjects: 20
Study: 21752394

Group type: EXPERIMENTAL
Intervention: Citalopram + Lithium
Number of subjects: 80

Group type: COMPARATOR
Intervention: Citalopram + Placebo
Number of subjects: 80
Study: 18456528

Group type: EXPERIMENTAL
Intervention: Monthly oral ibandronate 150mg
Number of subjects: 0
Study: 16431866

Group type: EXPERIMENTAL
Intervention: Providing game equipment during recess periods
Number of subjects: 235
Study: 15070004

Group type: EXPERIMENTAL
Intervention: Individuals with Williams syndrome (32 participants)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Individuals with Williams syndrome (15 participants)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control groups (matched for total number of errors and vocabulary ability)
Number of subjects: 47
Study: 11081890

Group type: EXPERIMENTAL
Intervention: Low dose aprotinin (n = 100)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Epsilon aminocaproic acid (n = 60)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Combination of aprotinin and epsilon aminocaproic acid (n = 60)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control group (n = 80)
Number of subjects: 300
Study: 9477875

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Local anesthesia
Number of subjects: 0
Study: 8437368

Group type: EXPERIMENTAL
Intervention: Pressure and volume-relief instrument (modified Brandt's rediffusion system)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Air inflation of endotracheal tube cuffs (Control group)
Number of subjects: 14
Study: 3096350

Group type: EXPERIMENTAL
Intervention: Oral L-carnitine supplementation (60 mumol/kg daily) for seven consecutive days
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (no L-carnitine supplementation)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Oral L-carnitine supplementation
Number of subjects: 10
Study: 30577048

Group type: EXPERIMENTAL
Intervention: FAB-sign test
Number of subjects: 100

Group type: COMPARATOR
Intervention: Lachman's test
Number of subjects: 100

Group type: COMPARATOR
Intervention: Pivot shift test
Number of subjects: 100
Study: 28819782

Group type: EXPERIMENTAL
Intervention: M2000 (β-D-mannuronic acid)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Naproxen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 26554853

Group type: COMPARATOR
Intervention: 30% FiO2
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: 80% FiO2
Number of subjects: 239
Study: 23848219

Group type: EXPERIMENTAL
Intervention: LST-HCTZ
Number of subjects: 176

Group type: COMPARATOR
Intervention: LST-AML
Number of subjects: 176
Study: 23027887

Group type: EXPERIMENTAL
Intervention: Rituximab (RTX) + Methotrexate (MTX)
Number of subjects: 480
Study: 20335153

Group type: EXPERIMENTAL
Intervention: Minocycline
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Metronidazole
Number of subjects: 123

Group type: COMPARATOR
Intervention: Iodine glycerin
Number of subjects: 123
Study: 17640830

Group type: EXPERIMENTAL
Intervention: Active bilateral tDCS (anodal left/cathodal right and anodal right/cathodal left)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 13
Study: 15856430

Group type: COMPARATOR
Intervention: CYP1A1*2A polymorphism
Number of subjects: 1134

Group type: COMPARATOR
Intervention: CYP1A1*2C polymorphism
Number of subjects: 1134

Group type: EXPERIMENTAL
Intervention: CYP1A1*2B homozygosity
Number of subjects: 1134

Group type: EXPERIMENTAL
Intervention: CYP1A1*2B homozygosity in postmenopausal women with long duration of menstruation (> 30 yrs)
Number of subjects: 1134

Group type: EXPERIMENTAL
Intervention: CYP1A1*2B homozygosity in women with low waist‐to‐hip ratio
Number of subjects: 1134
Study: 11919725

Group type: EXPERIMENTAL
Intervention: rhIL-11, 50 microg/kg subcutaneously daily for up to 21 days
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: rhIL-11
Number of subjects: 13
Study: 11252079

Group type: EXPERIMENTAL
Intervention: Magnesium oxide supplementation (212 mg.d-1)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 9260071

Group type: EXPERIMENTAL
Intervention: Alcohol (1.0 ml/kg)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Active placebo (0.1 ml/kg)
Number of subjects: 42
Study: 8504794

Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Phenobarbital
Number of subjects: 192

Group type: COMPARATOR
Intervention: Carbamazepine and Phenobarbital
Number of subjects: 192
Study: 3319172

Group type: EXPERIMENTAL
Intervention: Ceftizoxime
Number of subjects: 53

Group type: COMPARATOR
Intervention: Cefoxitin
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 53